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Background
Cardiac natriuretic peptides, atrial and brain natriuretic
peptides (ANP and BNP, respectively) are known to have
anti-cardiac hypertrophy effects. ANP and BNP bind to
their common receptor, guanylyl cyclase-A, which subse-
quently activates cGMP-protein kinase G (PKG) pathway.
Precise molecular mechanisms by which cardiac natriu-
retic peptides protect hearts against pathological cardiac
hypertrophy still remain unclear, however. Transient
receptor potential (TRP) C6, an ion channel responsible
for the receptor-activated Ca2+ entry, has been shown to
be a positive regulator of calcineurin-NFAT signaling
pathway that drives pathologic cardiac remodeling [1]. In
this study to elucidate the molecular pathways, by which
cardiac natriuretic peptides negatively regulate pro-hyper-
trophic signaling, we investigated effects of ANP on
TRPC6-calcineurin-NFAT signaling.
Results
In rat neonatal ventricular myocytes (NRVM), ANP signif-
icantly inhibited ET-1-induced Ca2+ entry and NFAT acti-
vation. The inhibitory effect of ANP on ET-1-induced Ca
entry was abolished in the presence of BTP2, a TRPC
inhibitor. In HEK293 cells expressing TRPC6, ANP dra-
matically inhibited TRPC6-mediated Ca2+ entry and cati-
onic currents. The inhibitory effect of ANP on TRPC6 was
abolished in the presence of specific PKG inhibitors or by
the substitution of alanine for threonine at 69th amino
acid of TRPC6, which has been shown to be phosphor-
ylated by PKG.
Conclusion
All these results suggest that inhibition of TRPC6 is an
important component, by which cardiac natriuretic pep-
tides-GC-A-cGMP-PKG signaling pathway protects the
hearts from pathological cardiac remodeling.
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